| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-81 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-775 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2015-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017513009-A |
| titleOfInvention |
Protein biomarkers for immune assessment and prediction of graft rejection |
| abstract |
The present invention provides a method for screening and detection of parenchymal organ transplant rejection in a subject comprising assaying a plasma, serum or blood patient sample from the subject for the protein markers identified herein. To do. An increase or decrease in the amount of marker present in a patient sample compared to a control sample indicates rejection and identifies a patient in need of biopsy or modified treatment. The method can be used to screen for patients at the risk of graft rejection without having to undergo a more expensive, risky and invasive biopsy procedure. [Selection] Figure 1B |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7073528-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021524906-A |
| priorityDate |
2014-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |